Overview

This trial is active, not recruiting.

Condition lymphoma
Sponsor Armando Santoro, MD
Start date January 2011
End date December 2013
Trial size 23 participants
Trial identifier NCT01891578, ONC/OSS-04/2010

Summary

Evaluation of immunological reconstitution after haploidentical BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide in patients with poor prognosis lymphoma

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
Evaluation of T lymphocytes and NK cells absolute number
time frame: 1 year

Secondary Outcomes

Measure
Evaluation of discrete T-cells populations
time frame: 1 year
Evaluation of antigen-specific T cell populations
time frame: 1 year
Evaluation of antigen-specific T lymphocyte's functionality
time frame: 1 year
Evaluation of cytokines production by IL-2 and anti-CD16 activated NK cells
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with lymphoma (any histology) relapsed after high dose chemotherapy and in partial remission, complete remission or stable disease after the last CT line that - Signed informed consent to perform an haploidentical allo-BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide Exclusion Criteria: none

Additional Information

Official title Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation Using a Nonmyeloablative Preparative Regimen and Post-transplant Cyclophosphamide, in Patients With Poor Prognosis Lymphomas
Principal investigator Armando Santoro, MD
Trial information was received from ClinicalTrials.gov and was last updated in June 2013.
Information provided to ClinicalTrials.gov by Istituto Clinico Humanitas.